News – Page 908 – Endpoints News

Prolific Insilico scores up to $200M deal in China; Researchers retract paper on gene involved in CRISPR baby ...

6 years ago

Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development

6 years ago

The new top 20 pharma list: Takeda jumps on, Biogen pushed out — and more big changes are on the way

6 years ago

A new player is taking the field in a push for a hemophilia A gene therapy, and it’s a big one

6 years ago

Rare disease clinical trials: FDA awards $15M in grants

6 years ago

BioMarin puts Lon Cardon in charge of portfolio strategy while gene therapy filings get underway

6 years ago

Stuck with a PhIII gene therapy failure at 96 weeks, GenSight prefers the upbeat assessment

6 years ago

FDA approves drug for rare condition that triggers intense pain from light exposure

6 years ago

Another one of Neil Woodford's portfolio companies escapes as UK biotech execs flee a collapse of faith

6 years ago

Jim Greenwood set to depart from BIO after US elections — vows to ensure lawmakers don't 'kill innovation'

6 years ago

Gilead files for filgotinib in Japan; Alzheimer's flop forces some painful next steps at Neurotrope

6 years ago

What does Nobel-quality research look like in action? Researchers recount the Bill Kaelin experiment

6 years ago

Following top-level C-suite departures, Ascletis raids Novartis for R&D exec

6 years ago

Merck enlists 4D Pharma's microbiome platform in a bid to build a new class of vaccines

6 years ago

Is FDA too lax with its drug approval standards? Senior FDA officials discuss

6 years ago

Drug price hikes, without justifiable new evidence of benefit — ICER analysis

6 years ago

'We're ripe': Cygnal draws the curtain on Flagship's latest bet on exoneural biology — and $65M in cash

6 years ago

Exclusive: GSK’s Hal Barron allies with Rick Klausner’s $600M cell therapy startup, looking to break new ground ...

6 years ago

Novartis nabs FDA approval for hyped Eylea rival

6 years ago

Novartis confidently breaks out mid-stage data on Xolair competitor

6 years ago

NGM Bio unveils positive PhII NASH results to some unimpressed investors

6 years ago

DBV's peanut allergy patch is finally under FDA review; Ritter swallows bitter pill to explore strategic alternatives

6 years ago

Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now

6 years ago

Gilead chief O'Day recruits top Genentech researcher as new CMO in the wake of a high-level R&D exodus

6 years ago

First page Previous page 905 906 907908909 910 911 Next page Last page